Postgraduate Medicine

Abstracts Published from the 17th Annual Cardiometabolic Health Congress

Retrieved on: 
Thursday, April 20, 2023

After the conclusion of last year's 17th Annual CMHC, all accepted and presented abstracts were published in the peer-reviewed Postgraduate Medicine, posted on the CMHC website and published in the post-show report.

Key Points: 
  • After the conclusion of last year's 17th Annual CMHC, all accepted and presented abstracts were published in the peer-reviewed Postgraduate Medicine, posted on the CMHC website and published in the post-show report.
  • Authors of accepted abstracts for the 18th Annual CMHC will be notified on or before Monday, September 11, 2023.
  • Accepted and presented abstracts in 2023 will once more be published in the peer-reviewed Postgraduate Medicine, posted on the CMHC website and published in the annual post-show report.
  • Providers in any field of medicine interested in whole-patient cardiometabolic and cardiorenal health are welcome to attend the event.

State of Wisconsin to Provide Access to Prescription Digital Therapeutics to Help Local Communities Fight Against Addiction Crisis

Retrieved on: 
Thursday, November 3, 2022

Eligible patients will be prescribed and treated with reSET or reSET-O to help communities throughout Wisconsin expand access to addiction care.

Key Points: 
  • Eligible patients will be prescribed and treated with reSET or reSET-O to help communities throughout Wisconsin expand access to addiction care.
  • The state of Wisconsin is making a difference for those struggling with addiction by expanding access to evidence-based treatment and recovery services, said Julia Strandberg, Chief Commercial Officer of Pear Therapeutics.
  • Reduced Healthcare Resource Utilization in Patients with Opioid Use Disorder in the 12 Months After Initiation of a Prescription Digital Therapeutic.
  • Evaluation of real-world outcomes associated with use of a prescription digital therapeutic to treat substance use disorders.

Pear Therapeutics Announces Publication of Real-World Data Showing High Rates of Engagement, Retention and Abstinence with reSET®

Retrieved on: 
Monday, October 24, 2022

reSET is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).

Key Points: 
  • reSET is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).
  • Patients should be clearly instructed not to use reSET to communicate to their clinician any urgent or emergent information.
  • Patients with substance use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population.
  • Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs).

Pear Therapeutics Announces New 12-Month Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Treated with reSET-O®

Retrieved on: 
Tuesday, June 14, 2022

The results of this analysis demonstrated that patients who were treated with reSET-O showed lower incidence of inpatient stays and emergency department visits, compared to control patients.

Key Points: 
  • The results of this analysis demonstrated that patients who were treated with reSET-O showed lower incidence of inpatient stays and emergency department visits, compared to control patients.
  • The study used claims data to evaluate 901 adult patients who were prescribed and treated with reSET-O compared to 978 controls.
  • Reduced healthcare resource utilization in patients with opioid use disorder in the 12 months after initiation of a prescription digital therapeutic.
  • Comparison of Healthcare Resource Utilization Between Patients Who Engaged or Did Not Engage With a Prescription Digital Therapeutic for Opioid Use Disorder.

Pear Therapeutics Announces State of Michigan to Fund Access to Prescription Digital Therapeutics for Substance Use and Opioid Use Disorders

Retrieved on: 
Thursday, February 10, 2022

With todays technology there is a lot more we can do and more people we can help, said Michigan State Representative Joe Bellino.

Key Points: 
  • With todays technology there is a lot more we can do and more people we can help, said Michigan State Representative Joe Bellino.
  • Pear recently released publications showing the potential for improved real-world health outcomes and decreased health care resource utilization for patients using reSET-O5-13.
  • Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs).
  • Comparison of Healthcare Resource Utilization Between Patients Who Engaged or Did Not Engage With a Prescription Digital Therapeutic for Opioid Use Disorder.

Pear Therapeutics to Further Support Point32Health Members in Recovery from Substance Use Disorders

Retrieved on: 
Thursday, January 13, 2022

We are delighted to again work with Pear Therapeutics to provide our members with high quality treatment options that will allow for tangible and measurable results.

Key Points: 
  • We are delighted to again work with Pear Therapeutics to provide our members with high quality treatment options that will allow for tangible and measurable results.
  • We are pleased to enter into this relationship with Point32Health to further support their members with access to innovative, FDA-authorized treatments for addiction without fear of stigma, said Julia Strandberg, Chief Commercial Officer at Pear Therapeutics.
  • Pear Therapeutics is a true collaborator, and we are excited to provide more of our members with access to this pioneering treatment option.
  • Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs).

Pear Therapeutics and Crossroads Treatment Centers to Provide More Patients Access to Prescription Digital Therapeutics as Standard of Care for the Treatment of Substance Use Disorders

Retrieved on: 
Wednesday, December 15, 2021

Crossroads is extremely excited to continue our cooperation with Pear Therapeutics, says Tripp Wylie, Director of Transformation for Crossroads.

Key Points: 
  • Crossroads is extremely excited to continue our cooperation with Pear Therapeutics, says Tripp Wylie, Director of Transformation for Crossroads.
  • With access to patient-reported data, our clinicians can provide measurement-based care throughout a patients treatment journey to help improve outcomes.
  • Crossroads has been providing outpatient medication-assisted treatment (MAT) for more than 16 years to people suffering from OUD.
  • This expansion underscores the shared commitment by both Crossroads and Pear to provide access to innovative treatment options in our fight against the growing addiction crisis.

Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the November 2021 MassHealth Drug List Summary Update and MassHealth Non-Drug Product List

Retrieved on: 
Tuesday, November 9, 2021

Pear Therapeutics, Inc. today announced the inclusion of Pears FDA-authorized prescription digital therapeutics (PDTs) reSET and reSET-O on the November 2021 MassHealth Drug List Summary Update .

Key Points: 
  • Pear Therapeutics, Inc. today announced the inclusion of Pears FDA-authorized prescription digital therapeutics (PDTs) reSET and reSET-O on the November 2021 MassHealth Drug List Summary Update .
  • MassHealth, Massachusetts Medicaid program, evaluates the prior-authorization status for drugs on an ongoing basis and updates the MassHealth Drug List accordingly.
  • Pears reSET and reSET-O will be paid for through MassHealths Pharmacy Online Processing System (POPS) and do not require prior authorization.
  • We are proud that reSET and reSET-O are the first digital therapeutics added to the MassHealth Non-Drug Product List and made available to Massachusetts residents enrolled in MassHealth, said Corey McCann, M.D., Ph.D., President and CEO of Pear Therapeutics.

Pear Therapeutics Announces Publication Showing Cost Savings and Decreased Hospital Encounters for Opioid Use Disorder Patients Treated with reSET-O® Compared to Control Patients During Nine-Month Period Following Prescription

Retrieved on: 
Wednesday, November 3, 2021

In the study, HCRU was measured during the nine-month period following a patients first prescription of reSET-O.

Key Points: 
  • In the study, HCRU was measured during the nine-month period following a patients first prescription of reSET-O.
  • The resulting net cost savings over the 9-month period of $2,708 per treated patient was largely driven by a 46% lower incidence of hospital-related stays.
  • The results of this analysis showed that patients who were treated with reSET-O showed substantially lower incidence of hospital encounters, particularly inpatient stays and ICU stays, compared to control patients.
  • Total cost of hospital facility encounters was lower for treated patients versus control patients ($2,693 versus $6,130, respectively), while total per-patient cost for clinical services was $6,040 for treated patients versus $5,311 for control patients.

Pear Therapeutics Announces First State Medicaid Program Decision to Cover Prescription Digital Therapeutics

Retrieved on: 
Wednesday, October 13, 2021

Pear Therapeutics, Inc. today announced MassHealth, Massachusetts Medicaid program, has notified Pear of its intent to cover Pears prescription digital therapeutics (PDTs) reSET and reSET-O to fight the growing substance and opioid addiction crisis.

Key Points: 
  • Pear Therapeutics, Inc. today announced MassHealth, Massachusetts Medicaid program, has notified Pear of its intent to cover Pears prescription digital therapeutics (PDTs) reSET and reSET-O to fight the growing substance and opioid addiction crisis.
  • We applaud MassHealth for their leadership in introducing PDTs to their Medicaid population to provide safe and effective treatment options for patients in recovery, said Corey McCann, M.D., Ph.D., President and CEO of Pear Therapeutics.
  • increase abstinence from a patients substances of abuse during treatment, and
    increase retention in the outpatient treatment program.
  • Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs.